<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36187720</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2329-0501</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><PubDate><Year>2022</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Molecular therapy. Methods &amp; clinical development</Title><ISOAbbreviation>Mol Ther Methods Clin Dev</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 infection increases the gene expression profile for Alzheimer's disease risk.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>229</EndPage><MedlinePgn>217-229</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtm.2022.09.007</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic has caused over 600,000,000 infections globally thus far. Up to 30% of individuals with mild to severe disease develop long COVID, exhibiting diverse neurologic symptoms including dementias. However, there is a paucity of knowledge of molecular brain markers and whether these can precipitate the onset of Alzheimer's disease (AD). Herein, we report the brain gene expression profiles of severe COVID-19 patients showing increased expression of innate immune response genes and genes implicated in AD pathogenesis. The use of a mouse-adapted strain of SARS-CoV-2 (MA10) in an aged mouse model shows evidence of viral neurotropism, prolonged viral infection, increased expression of tau aggregator FKBP51, interferon-inducible gene <i>Ifi204</i>, and complement genes C4 and C5AR1. Brain histopathology shows AD signatures including increased tau-phosphorylation, tau-oligomerization, and &#x3b1;-synuclein expression in aged MA10 infected mice. The results of gene expression profiling of SARS-CoV-2-infected and AD brains and studies in the MA10 aged mouse model taken together, for the first time provide evidence suggesting that SARS-CoV-2 infection alters expression of genes in the&#xa0;brain associated with the development of AD. Future studies of common molecular markers in SARS-CoV-2 infection and&#xa0;AD could be useful for developing novel therapies targeting AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayilsamy</LastName><ForeName>Karthick</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGill</LastName><ForeName>Andrew R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Taylor E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Bala</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL 33613, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bickford</LastName><ForeName>Paula C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging and Brain Repair, Departments of Neurosurgery and Brain Repair, and Molecular Pharmacology and Physiology, Morsani College of Medicine, Tampa, FL 33613, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohapatra</LastName><ForeName>Shyam S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohapatra</LastName><ForeName>Subhra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James A Haley VA Hospital, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 BX004626</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>IK6 BX004214</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>IK6 BX004212</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073899</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX005490</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA180758</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX005757</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Methods Clin Dev</MedlineTA><NlmUniqueID>101624857</NlmUniqueID><ISSNLinking>2329-0501</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS CoV-2</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36187720</ArticleId><ArticleId IdType="pmc">PMC9508696</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2022.09.007</ArticleId><ArticleId IdType="pii">S2329-0501(22)00132-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thies W., Bleiler L., Alzheimer's Association 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013;9:208&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">23507120</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D.S., Amieva H., Petersen R.C., Ch&#xe9;telat G., Holtzman D.M., Hyman B.T., Nixon R.A., Jones D.T. Alzheimer disease. Nat. Rev. Dis. Primers. 2021;7:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del Tredici K., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J.&#xa0;Neuropathol. Exp. Neurol. 2012;71:362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A., Schonhaut D.R., La Joie R., Kramer J.H., Baker S.L., Sosa N., Ayakta N., Cantwell A., Janabi M., Lauriola M., et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017;140:3286&#x2013;3300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C., Makaretz S.J., Caso C., McGinnis S., Gomperts S.N., Sepulcre J., Gomez-Isla T., Hyman B.T., Schultz A., Vasdev N., et al. Association of in&#xa0;vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74:427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470368</ArticleId><ArticleId IdType="pubmed">28241163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainberg M., Luquez T., Koelle D.M., Readhead B., Johnston C., Darvas M., Funk C.C. The viral hypothesis: how herpesviruses may contribute to Alzheimer's disease. Mol. Psychiatr. 2021;26:5476&#x2013;5480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758477</ArticleId><ArticleId IdType="pubmed">33972690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D., Antonini A., Leta V., Nordvig A., Smeyne R.J., Goldman J.E., Al-Dalahmah O., Zecca L., Sette A., Bubacco L., et al. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020;6:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7441399</ArticleId><ArticleId IdType="pubmed">32885037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J.P., Baker A.J. Influenza-associated neurological complications. Neurocrit. Care. 2013;18:118&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">23138546</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Liu C.C., Zheng H., Huang T.Y. Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. Transl. Neurodegener. 2018;7:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6306008</ArticleId><ArticleId IdType="pubmed">30603085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sy M., Kitazawa M., Medeiros R., Whitman L., Cheng D., Lane T.E., Laferla F.M. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am. J. Pathol. 2011;178:2811&#x2013;2822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124234</ArticleId><ArticleId IdType="pubmed">21531375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D.C., Rizer J., Selenica M.L.B., Reid P., Kraft C., Johnson A., Blair L., Gordon M.N., Dickey C.A., Morgan D. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J.&#xa0;Neuroinflammation. 2010;7:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949628</ArticleId><ArticleId IdType="pubmed">20846376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C., Venegas C., Zhang S., Scheiblich H., Schmidt S.V., Vieira-Saecker A., Schwartz S., Albasset S., McManus R.M., Tejera D., et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales I., Jim&#xe9;nez J.M., Mancilla M., Maccioni R.B. Tau oligomers and fibrils induce activation of microglial cells. J.&#xa0;Alzheimers Dis. 2013;37:849&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948931</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  WHO COVID-19 dashboard. 2020. https://covid19.who.int/</Citation></Reference><Reference><Citation>Malkova A., Kudryavtsev I., Starshinova A., Kudlay D., Zinchenko Y., Glushkova A., Yablonskiy P., Shoenfeld Y. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 2021;10:1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang R.D., Liu M.Q., Chen Y., Shan C., Zhou Y.W., Shen X.R., Li Q., Zhang L., Zhu Y., Si H.R., et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human Angiotensin-converting Enzyme 2. Cell. 2020;182:50&#x2013;58.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241398</ArticleId><ArticleId IdType="pubmed">32516571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Wang M., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., Li Y., Jin H., Hu B. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv. 2020 doi: 10.1101/2020.02.22.20026500. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.22.20026500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M., Ren Y., Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav. Immun. 2020;88:945&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146652</ArticleId><ArticleId IdType="pubmed">32283294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G.U., Kim M.J., Ra S.H., Lee J., Bae S., Jung J., Kim S.H. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin. Microbiol. Infect. 2020;26:948.e1&#x2013;948.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252018</ArticleId><ArticleId IdType="pubmed">32360780</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyrouti R., Adams M.E., Benjamin L., Cohen H., Farmer S.F., Goh Y.Y., Humphries F., J&#xe4;ger H.R., Losseff N.A., Perry R.J., et al. Characteristics of ischaemic stroke associated with COVID-19. J.&#xa0;Neurol. Neurosurg. Psychiatry. 2020;91:889&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231545</ArticleId><ArticleId IdType="pubmed">32354768</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A., Pilotto A., Premi E., Libri I., Giunta M., Agosti C., Alberici A., Baldelli E., Benini M., Bonacina S., et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020;95:e910&#x2013;e920.</Citation><ArticleIdList><ArticleId IdType="pubmed">32444493</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyiadji N., Shahin G., Noujaim D., Stone M., Patel S., Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. 2020;296:201187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233386</ArticleId><ArticleId IdType="pubmed">32228363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tape C., Byrd K.M., Aung S., Lonks J.R., Flanigan T.P., Rybak N.R. COVID-19 in a patient presenting with syncope and a normal chest X-ray. R.&#xa0;I. Med. J. 2020;103:50&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385703</ArticleId><ArticleId IdType="pubmed">32226962</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyiadji N., Shahin G., Noujaim D., Stone M., Patel S., Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. 2020;296:E119&#x2013;E120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233386</ArticleId><ArticleId IdType="pubmed">32228363</ArticleId></ArticleIdList></Reference><Reference><Citation>von Weyhern C.H., Kaufmann I., Neff F., Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020;395:e109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272176</ArticleId><ArticleId IdType="pubmed">32505222</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G., Lee S., Alfaro-Almagro F., Arthofer C., Wang C., McCarthy P., Lange F., Andersson J.L.R., Griffanti L., Duff E., et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y., Wu J., Chen T., Li J., Zhang G., Wu D., Zhou Y., Zheng N., Cai A., Ning Q., et al. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J.&#xa0;Clin. Invest. 2021;131:147329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262559</ArticleId><ArticleId IdType="pubmed">33630760</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell M.C., Green R., McGill A.R., Kahlil R.M., Dutta R., Mohapatra S.S., Mohapatra S. Activation of intracellular complement in lungs of patients with severe COVID-19 disease decreases T-cell activity in the lungs. Front. Immunol. 2021;12:700705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652259</ArticleId><ArticleId IdType="pubmed">34899680</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill A.R., Kahlil R., Dutta R., Green R., Howell M., Mohapatra S., Mohapatra S.S. SARS-CoV-2 immuno-pathogenesis and potential for diverse vaccines and therapies: opportunities and challenges. Infect. Dis. Rep. 2021;13:102&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931091</ArticleId><ArticleId IdType="pubmed">33557330</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Biswal M., Neal A., Hai R. Review Devil's tools: SARS-CoV-2 antagonists against innate immunity. Curr. Res. Virol. Sci. 2021;2:100013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598260</ArticleId><ArticleId IdType="pubmed">34812428</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldeck D., Larbi A., Pellican&#xf3; M., Alam I., Zerr I., Schmidt C., Fulop T., Pawelec G. Enhanced chemokine receptor expression on leukocytes of patients with Alzheimer's disease. PLoS One. 2013;8:e66664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3688934</ArticleId><ArticleId IdType="pubmed">23824053</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces M.R., Shcherbina A., Kundu S., Gloudemans M.J., Fr&#xe9;sard L., Granja J.M., Louie B.H., Eulalio T., Shams S., Bagdatli S.T., et al. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases. Nat. Genet. 2020;52:1158&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606627</ArticleId><ArticleId IdType="pubmed">33106633</ArticleId></ArticleIdList></Reference><Reference><Citation>Novikova G., Kapoor M., Tcw J., Abud E.M., Efthymiou A.G., Chen S.X., Cheng H., Fullard J.F., Bendl J., Liu Y., et al. Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat. Commun. 2021;12:1610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955030</ArticleId><ArticleId IdType="pubmed">33712570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuena A.R., Casolini P., Lattanzi R., Maftei D. Chemokines in Alzheimer's disease: new insights into prokineticins, chemokine-like proteins. Front. Pharmacol. 2019;10:622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568308</ArticleId><ArticleId IdType="pubmed">31231219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour H.M., Fawzy H.M., El-Khatib A.S., Khattab M.M. Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer's disease. Neural Regen. Res. 2022;17:1913&#x2013;1918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8848623</ArticleId><ArticleId IdType="pubmed">35142667</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C., Janelidze S., Hertze J., Zetterberg H., Blennow K., Mattsson-Carlgren N., Hansson O. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Res. Ther. 2021;13:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005231</ArticleId><ArticleId IdType="pubmed">33773595</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;lez J.I., Lopera F., Sepulveda-Falla D., Patel H.R., Johar A.S., Chuah A., Tob&#xf3;n C., Rivera D., Villegas A., Cai Y., et al. APOE&#x2217;E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Mol. Psychiatr. 2016;21:916&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5414071</ArticleId><ArticleId IdType="pubmed">26619808</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigas H.C., Ribeiro M., Coelho J.E., Gomes R., Gomez-Murcia V., Carvalho K., Faivre E., Costa-Pereira S., Darrigues J., de Almeida A.A., et al. IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease. Cell Rep. 2021;36:109574.</Citation><ArticleIdList><ArticleId IdType="pubmed">34469732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojala J.O., Sutinen E.M. The role of interleukin-18, oxidative stress and metabolic syndrome in Alzheimer's disease. J.&#xa0;Clin. Med. 2017;6:E55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447946</ArticleId><ArticleId IdType="pubmed">28531131</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddick P.C.G., Larson J.L., Rathore N., Bhangale T.R., Phung Q.T., Srinivasan K., Hansen D.V., Lill J.R., Alzheimer&#x2019;s Disease Genetic Consortium ADGC Alzheimer&#x2019;s Disease Neuroimaging Initiative ADNI. Pericak-Vance M.A., et al. A common variant of IL-6R is associated with elevated IL-6 pathway activity in Alzheimer's disease brains. J.&#xa0;Alzheimers Dis. 2017;56:1037&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5667357</ArticleId><ArticleId IdType="pubmed">28106546</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Z., Zou X., Jin Y., Gao S., Lv J., Li B., Cui R. The role of KLF4 in Alzheimer's disease. Front. Cell. Neurosci. 2018;12:325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6160590</ArticleId><ArticleId IdType="pubmed">30297986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Zheng Y., Xu D., Sun Z., Yang H., Yin Q. Galectin-3: a key player in microglia-mediated neuroinflammation and Alzheimer's disease. Cell Biosci. 2021;11:78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077955</ArticleId><ArticleId IdType="pubmed">33906678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao C.C., Cheng K.M., Ma Y.L., Hsu W.L., Chen Y.C., Fuh J.L., Lee W.J., Chao C.C., Lee E.H.Y. Galectin-3 promotes Abeta oligomerization and Abeta toxicity in a mouse model of Alzheimer's disease. Cell Death Differ. 2020;27:192&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206130</ArticleId><ArticleId IdType="pubmed">31127200</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharshini S.A.P., Taguchi Y.H., Gromiha M.M. Investigating the energy crisis in Alzheimer disease using transcriptome study. Sci. Rep. 2019;9:18509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898285</ArticleId><ArticleId IdType="pubmed">31811163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudreault S.B., Dea D., Poirier J. Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiol. Aging. 2004;25:753&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15165700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Pavlov P.F., Kumar R., Winblad B. FKBP51-Hsp90 complex as a novel therapeutic target for Alzheimer&#x2019;s disease. Alzheimers Dement. 2020;16</Citation></Reference><Reference><Citation>Fujii T., Ota M., Hori H., Hattori K., Teraishi T., Matsuo J., Kinoshita Y., Ishida I., Nagashima A., Kunugi H. The common functional FKBP5 variant rs1360780 is associated with altered cognitive function in aged individuals. Sci. Rep. 2014;4:6696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4204028</ArticleId><ArticleId IdType="pubmed">25331639</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair L.J., Nordhues B.A., Hill S.E., Scaglione K.M., O'Leary J.C., 3rd, Fontaine S.N., Breydo L., Zhang B., Li P., Wang L., et al. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J.&#xa0;Clin. Invest. 2013;123:4158&#x2013;4169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784538</ArticleId><ArticleId IdType="pubmed">23999428</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair L.J., Sabbagh J.J., Dickey C.A. Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease. Expert Opin. Ther. Targets. 2014;18:1219&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625388</ArticleId><ArticleId IdType="pubmed">25069659</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler D.A., Klaver A.C., Coffey M.P., Aasly J.O., LeWitt P.A. Age-related decrease in heat shock 70-kDa protein 8 in cerebrospinal fluid is associated with increased oxidative stress. Front. Aging Neurosci. 2016;8:178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4960228</ArticleId><ArticleId IdType="pubmed">27507943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur J.Y. Innate immunity protein IFITM3 in Alzheimer's disease. DNA Cell Biol. 2021;40:1351&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pubmed">34468206</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner A.J. Complement-mediated events in Alzheimer's disease: mechanisms and potential therapeutic targets. J.&#xa0;Immunol. 2020;204:306&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6951444</ArticleId><ArticleId IdType="pubmed">31907273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez M.X., Jiang S., Cole T.A., Chu S.H., Fonseca M.I., Fang M.J., Hohsfield L.A., Torres M.D., Green K.N., Wetsel R.A., et al. Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss. Mol. Neurodegener. 2017;12:66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604420</ArticleId><ArticleId IdType="pubmed">28923083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X.C., Yu J.T., Jiang T., Wang P., Cao L., Tan L. CR1 in Alzheimer's disease. Mol. Neurobiol. 2015;51:753&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">24794147</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanfilippo C., Castrogiovanni P., Imbesi R., Di Rosa M. CHI3L2 expression levels are correlated with AIF1, PECAM1, and CALB1 in the brains of Alzheimer's disease patients. J.&#xa0;Mol. Neurosci. 2020;70:1598&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">32705525</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbir M.G. Loss of Ca(2+)/calmodulin dependent protein kinase kinase 2 leads to aberrant transferrin phosphorylation and trafficking: a potential biomarker for Alzheimer's disease. Front. Mol. Biosci. 2018;5:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256988</ArticleId><ArticleId IdType="pubmed">30525042</ArticleId></ArticleIdList></Reference><Reference><Citation>Mairet-Coello G., Courchet J., Pieraut S., Courchet V., Maximov A., Polleux F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron. 2013;78:94&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784324</ArticleId><ArticleId IdType="pubmed">23583109</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott E., Atlas R., Lange A., Ginzburg I. Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism. Eur. J. Neurosci. 2005;22:1081&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">16176349</ArticleId></ArticleIdList></Reference><Reference><Citation>Plagman A., Hoscheidt S., McLimans K.E., Klinedinst B., Pappas C., Anantharam V., Kanthasamy A., Willette A.A., Alzheimer's Disease Neuroimaging Initiative Cholecystokinin and Alzheimer's disease neuroimaging. Neurobiol. Aging. 2019;76:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425756</ArticleId><ArticleId IdType="pubmed">30739077</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Kawarai T., Meng Y., Lee J.H., Lee H.S., Wakutani Y., Shibata E., Pathan N., Bi A., Sato C., et al. Association studies between the plasmin genes and late-onset Alzheimer's disease. Neurobiol. Aging. 2007;28:1041&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647723</ArticleId><ArticleId IdType="pubmed">16828203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W., Konsolaki M. FKBP immunophilins and Alzheimer's disease: a chaperoned affair. J.&#xa0;Biosci. 2011;36:493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">21799260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur J.Y., Frost G.R., Wu X., Crump C., Pan S.J., Wong E., Barros M., Li T., Nie P., Zhai Y., et al. The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer's disease. Nature. 2020;586:735&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919141</ArticleId><ArticleId IdType="pubmed">32879487</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy E.R., Wang B., Wan Y.W., Chiu G., Cole A., Yin Z., Propson N.E., Xu Y., Jankowsky J.L., Liu Z., et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J.&#xa0;Clin. Invest. 2020;130:1912&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108898</ArticleId><ArticleId IdType="pubmed">31917687</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulon P.G., Dhanushkodi N., Prakash S., Srivastava R., Roy S., Alomari N.I., Nguyen A.M., Warsi W.R., Ye C., Carlos-Cruz E.A., et al. NLRP3, NLRP12, and IFI16 inflammasomes induction and caspase-1 activation triggered by virulent HSV-1 strains are associated with severe corneal inflammatory herpetic disease. Front. Immunol. 2019;10:1631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6644090</ArticleId><ArticleId IdType="pubmed">31367214</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiken S., Sittenfeld L., Dridi H., Liu Y., Liu X., Marks A.R. Alzheimer's-like signaling in brains of COVID-19 patients. Alzheimers Dement. 2022;18:955&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011576</ArticleId><ArticleId IdType="pubmed">35112786</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Viramontes N.I., Campa-C&#xf3;rdoba B.B., Ontiveros-Torres M.&#xc1;., Harrington C.R., Villanueva-Fierro I., Guadarrama-Ort&#xed;z P., Garc&#xe9;s-Ram&#xed;rez L., de la Cruz F., Hernandes-Alejandro M., Mart&#xed;nez-Robles S., et al. PHF-core tau as the potential initiating event for tau pathology in Alzheimer's disease. Front. Cell. Neurosci. 2020;14:247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511711</ArticleId><ArticleId IdType="pubmed">33132840</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward S.M., Himmelstein D.S., Lancia J.K., Binder L.I. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem. Soc. Trans. 2012;40:667&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704193</ArticleId><ArticleId IdType="pubmed">22817713</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinisi A., Flach M., Sprenger F., Frank S., Tolnay M., Winkler D.T. Severe oligomeric tau toxicity can be reversed without long-term sequelae. Brain. 2021;144:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8041046</ArticleId><ArticleId IdType="pubmed">33484116</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiei S.S., Guerrero-Mu&#xf1;oz M.J., Castillo-Carranza D.L. Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Front. Aging Neurosci. 2017;9:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378766</ArticleId><ArticleId IdType="pubmed">28420982</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair L.J., Frauen H.D., Zhang B., Nordhues B.A., Bijan S., Lin Y.C., Zamudio F., Hernandez L.D., Sabbagh J.J., Selenica M.L.B., Dickey C.A. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol. Commun. 2015;3:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353464</ArticleId><ArticleId IdType="pubmed">25775028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Xu J., Xu S.J., Guo J.J., Wang F., Wang Q.W. Analysis and identification genetic effect of SARS-CoV-2 infections to Alzheimer's disease patients by integrated bioinformatics. J.&#xa0;Alzheimers Dis. 2022;85:729&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">34776447</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M., Penn C., Martinez T., Mayilsamy K., McGill A., Wiling A., Mohapatra S.S., Mohapatra S. COVID-19 neurotropism and implications for therapy. Neuroimmunol. Neuroinflamm. 2020;7:141&#x2013;149.</Citation></Reference><Reference><Citation>Rutkai I., Mayer M.G., Hellmers L.M., Ning B., Huang Z., Monjure C.J., Coyne C., Silvestri R., Golden N., Hensley K., et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat. Commun. 2022;13:1745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8975902</ArticleId><ArticleId IdType="pubmed">35365631</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomer E., Buechler J., Salinas P.C. Wnt signaling deregulation in the aging and Alzheimer's brain. Front. Cell. Neurosci. 2019;13:227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538920</ArticleId><ArticleId IdType="pubmed">31191253</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaks C.E., Wilcock D.M. Infectious hypothesis of Alzheimer disease. PLoS Pathog. 2020;16:e1008596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660461</ArticleId><ArticleId IdType="pubmed">33180879</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott A. Are infections seeding some cases of Alzheimer's disease? Nature. 2020;587:22&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33149296</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig D., Nielsen H.M. alpha-synuclein in the pathophysiology of Alzheimer's disease. Mol. Neurodegener. 2019;14:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6558879</ArticleId><ArticleId IdType="pubmed">31186026</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Kaether C., Thinakaran G., Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012;2:a006270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Winslow A.R., Moussaud S., Zhu L., Post K.L., Post K.L., Dickson D.W., Berezovska O., McLean P.J. Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain. 2014;137:1958&#x2013;1970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065023</ArticleId><ArticleId IdType="pubmed">24860142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko H., Kakita A., Kasuga K., Nozaki H., Ishikawa A., Miyashita A., Kuwano R., Ito G., Iwatsubo T., Takahashi H., et al. Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease. J.&#xa0;Neurosci. 2007;27:13092&#x2013;13097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673391</ArticleId><ArticleId IdType="pubmed">18045903</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.&#xa0;Roy. Stat. Soc. B. 1995;57:289&#x2013;300.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>